Hormone replacement therapy, thrombosis and thrombophilia.
Hormone replacement therapy increases the risk of venous thromboembolism. The risk is already increased in those with a personal or family history of thrombosis and in those with a hereditary thrombophilia. This article gives estimates of the absolute risk of using hormone replacement therapy and practical advice on its use in these groups and on the role of thrombophilia screening.
Keeling
David M
DM
Oxford Radcliffe Hospitals, Oxford OX3 7LJ, UK. david.keeling@ndm.ox.ac.uk
D000368:Aged; D005260:Female; D005500:Follow-Up Studies; D020249:Hormone Replacement Therapy / Q000009:adverse effects* / Q000592:standards; D006801:Humans; D008593:Menopause / Q000187:drug effects* / Q000502:physiology; D008875:Middle Aged; D008991:Monitoring, Physiologic; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D019851:Thrombophilia / Q000139:chemically induced* / Q000453:epidemiology; D006113:United Kingdom; D020246:Venous Thrombosis / Q000139:chemically induced* / Q000453:epidemiology